TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On cluster level, hospitals with emergency surgical admissions performing laparoscopic appendectomies are eligible for inclusion.~* On an individual level, participants are eligible for inclusion if they undergo a laparoscopic appendectomy for appendicitis (both uncomplicated and complicated), are ≥ 18 years of age, and provide a signed written consent form.~Exclusion Criteria:~* Exclusion criteria are specifically related to the therapy and individual participants will be excluded if they undergo any other procedures than laparoscopic appendectomy during index surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1- Postoperative Course (Type: ACTIVE_COMPARATOR): Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.~Last 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.
- Arm 2 - Postoperative Course (Type: ACTIVE_COMPARATOR): Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.~Last 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with rheumatoid arthritis at least 3 months prior to registration and who are definitely identified as having rheumatoid arthritis, at the time of informed consent, according to the criteria for classification established by the American College of Rheumatology (1987)~* Patients who have previously not responded to at least one DMARD (before informed consent is obtained)~* Patients who, if they are on the treatment with a DMARD, the DMARD can be washed out for at least 4 weeks before the first administration~* Patients having at least 6 swollen joints and 6 tender joints at the time of registration and immediately before the first injection~Exclusion Criteria:~* Patients with a history of hypersensitivity to human immunoglobulin proteins or other ingredients of golimumab~* Patients who have previously experienced or are suffering from any of the following diseases: (i) Collagen diseases other than rheumatoid arthritis, (ii) Latent or active granulomatous infections such as histoplasmosis and coccidioidomycosis, (iii) Felty syndrome, etc~* Patients with a severe, advanced, or poorly controlled disease in any of the kidney, liver, blood, gastrointestinal system, endocrine system, lung, heart, nervous system, psychiatric system, and brain

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- CNTO 148 50 mg (Type: EXPERIMENTAL): None
- CNTO 148 100 mg (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-75 years~* Recently diagnosed with severe sleep apnea and do not have any previous experience or information with this pathology~* Consent signed~Exclusion Criteria:~* BMI \> 40 kg/m²~* Inability to fill up questionnaires~* Severe drug or alcohol abuse~* Hypnotic medication~* Not controlled coronary disease~* Decompensated Heart failure~* Stroke~* Systemic Disease associated with inflammatory diagnosed entity (arthritis, sarcoidosis, vasculitis, lupus...)~* Neuromuscular disease (like Duchenne)~* Craniofacial deformities.~* Active oncologic process.~* Any antecedents of MT treatment or other treatment for sleep apnea could affect study results of the study (surgery, Mandibular Advancement Device (MAD) or CPAP).~Once the patient accepted and signed consent and met inclusion criteria, they will be attended by Ent specialist to rule out:~* Severe upper airway obstruction (Complete nose obstruction, Tonsils grade IV/IV )~* Presence of tongue tie (Marchesani protocol) with limitation of tongue movements~* Antecedents or presence of temporomandibular joint disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- INTERVENTION (AirwayGym) GROUP (Type: EXPERIMENTAL): Patients newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the AirwayGym app for 20 min a day for 90 days.
- CONTROL GROUP (Type: NO_INTERVENTION): Patients newly diagnosed with severe OSAHS do no therapy for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adolescent (≥12 years to \<18 years, and weighing ≥40 kg).~2. Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit.~3. Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit.~4. Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit~5. ≥10% body surface area (BSA) of AD involvement at the baseline visit.~6. History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.~Exclusion Criteria:~1. Participation in a prior lebrikizumab clinical study.~2. Treatment with the following prior to the baseline visit:~   1. An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer.~  2. Dupilumab within 8 weeks.~  3. B-cell-depleting biologics, including to rituximab, within 6 months.~  4. Other biologics within 5 half-lives (if known) or 16 weeks, whichever is longer.~3. Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study.~4. Uncontrolled chronic disease that might require bursts of oral corticosteroids.~5. Evidence of active acute or chronic hepatitis~6. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.~7. History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.~8. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lebrikizumab 250 mg (Type: EXPERIMENTAL): Participants received two subcutaneous (SC) injections of 250 milligram(mg) Lebrikizumab at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 up to (but not including) Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females ≥18 years of age.~* American Society of Anesthesiologists (ASA) physical status 1 or 2.~* Female subjects must be surgically sterile, at least 2 years postmenopausal, or using a medically acceptable method of birth control. If of childbearing potential, must have a documented negative pregnancy test within 24 hours before the first study drug administration.~* Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.~Exclusion Criteria:~* History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics.~* History of abnormal bleeding tendencies/clotting disorders.~* Regular use of anticoagulants (except for low dose aspirin for cardioprotection).~* Received any investigational drug within 30 days prior to study drug administration, and/or has planned administration of another investigational product or procedure during his/her participation in this study.~* Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.~* Subjects with significant medical conditions or laboratory results that, in the opinion of the Investigator, would constitute a contraindication to participation in the study, or cause inability to comply with the study requirements.~* Received bupivacaine or other local anesthetic within 7 days of first study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: ACTIVE_COMPARATOR): Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
- Cohort 2 (Type: ACTIVE_COMPARATOR): Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
- Cohort 3 (Type: ACTIVE_COMPARATOR): Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
- Cohort 4 (Type: ACTIVE_COMPARATOR): Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
- Cohort 5 (Type: ACTIVE_COMPARATOR): Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between 12 and 75 years of age with active type 1 FMF disease (according to Tel-Hashomer criteria for diagnosis of FMF) despite colchicine therapy (1.5 to 2.0 mg/day).~* Patients who are intolerant to effective doses of colchicine (1.5 to 2 mg/day)~* Patients with demonstrated minimum 1 typical acute attack per month and genetic confirmation of diagnosis (with at least one of the known MEFV gene exon 10 mutations). Patients with manifested amyloidosis are excluded.~* Patients must have a historical data showing a frequency of at least 1 attack/month within the last 3 months before they can be enter the run-in period.~* Patients must have type 1 disease characterized by recurrent and short episodes of inflammation and serositis with an average of at least 1 documented acute FMF attack per month during the previous 6 months and lasting approximately 12 to 72 hours.~* Patients treated with IL-1 therapies must complete washout and have experienced at least 2 attacks since (e.g. Anakinra: 3 day washout; Rilonacept: 3 week washout)~* Patients treated with anti-TNF drugs must undergo appropriate washout. Prior to randomization, use of Etanercept must be discontinued for 4 weeks or use of Adalimumab or Infliximab must be discontinued for 8 weeks.~* Female subjects of childbearing potential must be using two acceptable methods of contraception~* Patients treated with Interferon therapies must complete 1 month washout period.~Exclusion Criteria:~* Patients with end-organ dysfunction due to amyloidosis (e.g. existing biopsy proven amyloidosis or proteinuria \> 0.5 gram per day)~* Patients taking steroids within 1 month prior to baseline~* Presence or history of any other inflammatory rheumatic disease~* Positive PPD test (according to local guidance) where a latent or active TB infection cannot be excluded via Quantiferon (T-Spot or radiographic imaging if needed).~* Patients who are pregnant or lactating~* Presence of any active or chronic infection or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 30 days or oral antibiotics within 14 days prior to screening~* History or a malignancy within the last 5 years, except for successfully excised squamous or basal cell carcinoma of the skin~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a pathologic diagnosis of malignancy~2. Patients with any radiographic evidence of bone metastases, including plain x-ray, bone scan, computed tomography (CT) scan, magnetic resonance imaging (MRI), or positron emission tomography (PET) scan~3. Patients with pain or dysaesthesia~4. Patients with a life expectancy of more than 3 months~5. Patients able to complete pain assessment and quality of life surveys~6. Patients with multiple osseous sites are eligible; however should not treat more than 3 separate radiation treatment fields concurrently.~7. Patients with surgery for osseous metastases are allowed.~Exclusion Criteria:~1. Patients with prior radiation therapy to the treatment site~2. Patients with a current, untreated spinal cord compression~3. Patients with a radiographic or pathologic fracture to the treatment site~4. Patients with painful metastases to hands and feet that need to be radiated on protocol~5. Patients previously treated with radioactive isotope (e.g. Sr89) within 30 days of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hypofractionated Radiation Therapy (Type: EXPERIMENTAL): Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
- One Radiation Therapy Treatment (Type: ACTIVE_COMPARATOR): 12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for the Treatment of Painful Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients at least 18 years of age.~* Patients with pain due to diabetic neuropathy in both legs.~* Females must not be pregnant or plan to become pregnant during the study.~* Stable Glycemic control.~* Average mean pain severity score of at least 4.0 as assessed by completion of a daily diary.~Exclusion Criteria:~* You are related to or work for the physician conducting the study or are employed by Eli Lilly and Company.~* You have a severe or serious medical condition that causes you to be hospitalized often; or you have had a kidney transplant or are on current dialysis.~* You have participated in a study for an investigational drug within the last 30 days.~* You have a history of major depressive disorder, generalized anxiety disorder, or alcohol or eating disorders.~* You have a past medical history or diagnosis of mania, bipolar disorder, or psychosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females or males age 18-90 able to give informed consent~* Undergoing bilateral mastectomy with immediate expander reconstruction or immediate implant reconstruction~* May have either malignant or benign breast condition~Exclusion Criteria:~* Antibiotic use in the fourteen days prior to surgical date~* Undergoing unilateral tissue expander reconstruction~* Documented allergy to chlorhexidine gluconate~* Prior radiation therapy to the breast or chest wall (ie for breast conservation or mantle radiation for Hodgkin's disease)~* Documented allergy to all three of the following antibiotics: cephalosporin, trimethoprim/sulfamethoxazole, and levofloxacin~* Pregnant women~* Vulnerable subjects - prisoners, institutionalized individuals~* Non-English speaking patients without adequate interpreter assistance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Antisepsis Side (Type: EXPERIMENTAL): A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days. The drainage bulb will be irrigated with 10ml of 0.125% sodium hypochlorite (Dakin's solution) twice a day.
- Control Side (Type: OTHER): Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete